Steatohepatitis/Metabolic Liver Disease News

An analysis of data from a small cohort of children with type 2 diabetes and nonalcoholic fatty liver disease, or NAFLD, suggests that nonalcoholic steatohepatitis, or NASH, is common among these patients, with 26% showing signs of advanced fibrosis, according to findings published in Pediatric Diabetes.

HighTide Therapeutics received FDA fast track designation for its investigational drug HTD1801 for the treatment of patients with nonalcoholic steatohepatitis, according to a press release.

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Rob Myers, MD, senior director of the liver diseases therapeutic area at Gilead Sciences, discusses the company’s therapeutic pipeline for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

This year at The Liver Meeting, several researchers presented data on recent advances in clinical therapeutics for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, as well as data on increasing incidence trends and discussions on the need for improved awareness.

Perspectum Diagnostics released details regarding the latest version of its LiverMultiScan magnetic resonance imaging technology which identified nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release.

TARGET PharmaSolutions has partnered with Gilead Sciences for the TARGET-NASH observational study of nonalcoholic fatty liver disease and the TARGET-HBV observational study of hepatitis B, according to a press release.

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Zobair M. Younossi, MD, chairman of the department of medicine at Inova Fairfax Hospital in Virginia, discusses several presentations on patient reported-outcomes and mortality related to nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Researchers from George Washington University received a grant of approximately $2.4 million from the National Institutes of Health to investigate the role of forebrain and hypothalamic endoplasmic reticulum stress in obesity-induced hepatic sympathetic overactivity and nonalcoholic fatty liver disease development, according to a press release.

SAN FRANCISCO — In this exclusive video from The Liver Meeting 2018, Sven Henrichwark, CEO of Echosens, discusses the company’s Fibroscan technology and the potential to combine Fibroscan with new biomarkers and scoring systems.

SAN FRANCISCO — A novel thyroid receptor agonist – MGL-3196 – showed a sustained reduction in liver fat and other markers of nonalcoholic steatohepatitis in a 36-week study, according to data presented at The Liver Meeting 2018.